Antibe Therapeutics (ATBPF) Short Interest Ratio & Short Volume → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free ATBPF Stock Alerts $0.22 0.00 (0.00%) (As of 05/8/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesShort Interest Antibe Therapeutics Short Interest DataCurrent Short Volume65,100 sharesPrevious Short Volume3,200 sharesChange Vs. Previous Month+1,934.38%Dollar Volume Sold Short$14,035.56Short Interest Ratio / Days to Cover0.7Last Record DateApril 15, 2024Outstanding Shares53,010,000 sharesPercentage of Shares Shorted0.12%Today's Trading Volume0 sharesAverage Trading Volume1,697 sharesToday's Volume Vs. Average0% Short Selling Antibe Therapeutics ? Sign up to receive the latest short interest report for Antibe Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatATBPF Short Interest Over TimeATBPF Days to Cover Over TimeATBPF Percentage of Float Shorted Over Time Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… Antibe Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/202465,100 shares $14,035.56 +1,934.4%N/A0.7 $0.22 3/31/20243,200 shares $1,070.40 -64.0%N/A0.1 $0.33 3/15/20248,900 shares $2,891.61 -73.1%N/A0.1 $0.32 2/29/202433,100 shares $23,653.26 +234.3%N/A0.5 $0.71 2/15/20249,900 shares $6,811.20 No ChangeN/A0.6 $0.69 1/15/202410,400 shares $8,112.00 -9.6%N/A1.4 $0.78 Get the Latest News and Ratings for ATBPF and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/31/202311,500 shares $7,843.00 +121.2%N/A0.7 $0.68 12/15/20235,200 shares $3,571.88 -17.5%N/A1.1 $0.69 11/30/20236,300 shares $3,433.50 -54.0%N/A0.8 $0.55 11/15/202313,700 shares $7,521.30 +17.1%N/A0.1 $0.55 10/31/202311,700 shares $5,382.00 -27.8%N/A0.2 $0.46 10/15/202316,200 shares $5,799.60 +211.5%N/A1.7 $0.36 9/30/20235,200 shares $1,863.06 -24.6%N/A0.2 $0.36 9/15/20236,900 shares $2,829.00 -76.4%N/A0.3 $0.41 8/31/202329,200 shares $11,554.44 -22.8%N/A1.1 $0.40 8/15/202337,800 shares $15,498.00 +563.2%N/A1.5 $0.41 7/31/20235,700 shares $2,053.14 -8.1%N/A0.4 $0.36 7/15/20236,200 shares $2,156.98 No ChangeN/A2.8 $0.35 6/30/20236,200 shares $2,170.00 -7.5%N/A2.6 $0.35 6/15/20236,700 shares $2,517.19 -71.7%N/A1.6 $0.38 5/31/202323,700 shares $8,752.41 +203.9%N/A1.3 $0.37 5/15/20237,800 shares $2,934.36 -27.8%N/A0.6 $0.38 4/30/202310,800 shares $4,342.68 -6.9%N/A3.1 $0.40 4/15/202311,600 shares $4,637.68 -78.6%N/A3.6 $0.40 3/31/202354,100 shares $23,766.13 -1.3%N/A2.5 $0.44 3/15/202354,800 shares $20,643.16 +260.5%N/A1.2 $0.38 2/28/202315,200 shares $5,668.08 -37.5%N/A1.7 $0.37 2/15/202324,300 shares $10,529.19 +22.7%N/A4.9 $0.43 1/31/202319,800 shares $8,401.14 +94.1%N/A0.8 $0.42 1/15/202310,200 shares $5,115.81 -56.8%N/A4.3 $0.50 12/30/202223,600 shares $7,622.80 -23.1%N/A2.5 $0.32 12/15/202230,700 shares $11,666.00 +44.8%N/A2.8 $0.38 11/30/202221,200 shares $7,420.00 +32.5%N/A3.2 $0.35 11/15/202216,000 shares $5,912.00 +3.9%N/A1.3 $0.37 10/31/202215,400 shares $5,998.30 +12.4%N/A3.1 $0.39 10/15/202213,700 shares $5,555.35 -8.7%N/A3 $0.41 9/30/202215,000 shares $6,718.50 -41.4%N/A1.1 $0.45 9/15/202225,600 shares $12,170.24 -13.8%N/A2.8 $0.48 8/31/202229,700 shares $14,362.92 -15.1%N/A2.3 $0.48 8/15/202235,000 shares $17,570.00 -39.2%N/A3.3 $0.50The 2024 Gold Rush: Unleashing Market Potential (Ad)Welcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. ATBPF Short Interest - Frequently Asked Questions What is Antibe Therapeutics' current short interest? Short interest is the volume of Antibe Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 15th, traders have sold 65,100 shares of ATBPF short. Learn More on Antibe Therapeutics' current short interest. What is a good short interest ratio for Antibe Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ATBPF shares currently have a short interest ratio of 1.0. Learn More on Antibe Therapeutics's short interest ratio. Is Antibe Therapeutics' short interest increasing or decreasing? Antibe Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 65,100 shares, an increase of 1,934.4% from the previous total of 3,200 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Antibe Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Antibe Therapeutics: Akari Therapeutics, Plc (0.01%), Moleculin Biotech, Inc. (1.24%), Elevai Labs, Inc. (0.32%), MIRA Pharmaceuticals, Inc. (0.43%), ABVC BioPharma, Inc. (6.14%), Eterna Therapeutics Inc. (1.35%), Molecular Templates, Inc. (6.97%), BetterLife Pharma Inc. (0.01%), Imunon, Inc. (4.96%), Guardion Health Sciences, Inc. (14.39%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Antibe Therapeutics stock? Short selling ATBPF is an investing strategy that aims to generate trading profit from Antibe Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Antibe Therapeutics? A short squeeze for Antibe Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ATBPF, which in turn drives the price of the stock up even further. How often is Antibe Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ATBPF, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Akari Therapeutics Short Interest Data Moleculin Biotech Short Interest Data Elevai Labs Short Interest Data MIRA Pharmaceuticals Short Interest Data ABVC BioPharma Short Interest Data Eterna Therapeutics Short Interest Data Molecular Templates Short Interest Data BetterLife Pharma Short Interest Data Imunon Short Interest Data Guardion Health Sciences Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:ATBPF) was last updated on 5/9/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmithDems have chosen Biden replacement?Paradigm PressGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchObama’s Forever Term [exposed]Porter & CompanyPOTUS in ‘25 Not Biden/Trump, ButThe Freeport Society